OTCMKTS:NRXGQ - NephroGenex Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.0028 0.00 (0.00 %)
(As of 06/25/2018 12:20 PM ET)
Previous Close$0.0028
Today's Range$0.0028 - $0.0028
52-Week Range$0.0020 - $0.21
Volume2,000 shs
Average Volume26,223 shs
Market Capitalization$36,250.00
P/E RatioN/A
Dividend YieldN/A
NephroGenex logoNephroGenex, Inc. is a pharmaceutical company. The Company is focused on the development of therapeutics to treat kidney disease. The Company has paused the clinical program of its product candidate, oral Pyridorin, for the treatment of diabetic nephropathy. The Company was primarily focused on the Phase III Pyridorin program, and other planned clinical and nonclinical studies and other work needed to submit Pyridorin for acute kidney injury (AKI), as well as the treatment of diabetic nephropathy in patients with Type II diabetes for regulatory approval in the United States and Europe. The Company has not generated any revenues.

Receive NRXGQ News and Ratings via Email

Sign-up to receive the latest news and ratings for NRXGQ and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A


Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A


EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on Equity-211.97%
Return on Assets-105.90%


Outstanding Shares12,950,000

The Truth About Cryptocurrencies

NephroGenex (OTCMKTS:NRXGQ) Frequently Asked Questions

What is NephroGenex's stock symbol?

NephroGenex trades on the OTCMKTS under the ticker symbol "NRXGQ."

How were NephroGenex's earnings last quarter?

NephroGenex Inc (OTCMKTS:NRXGQ) posted its quarterly earnings data on Wednesday, November, 11th. The healthcare company reported ($0.53) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.65) by $0.12. View NephroGenex's Earnings History.

Who are NephroGenex's key executives?

NephroGenex's management team includes the folowing people:
  • John P. Hamill CPA, Chief Executive Officer, Chief Financial Officer

Has NephroGenex been receiving favorable news coverage?

News coverage about NRXGQ stock has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. NephroGenex earned a media sentiment score of 0.16 on Accern's scale. They also assigned media coverage about the healthcare company an impact score of 45.82 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term.

How do I buy shares of NephroGenex?

Shares of NRXGQ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is NephroGenex's stock price today?

One share of NRXGQ stock can currently be purchased for approximately $0.0028.

How big of a company is NephroGenex?

NephroGenex has a market capitalization of $36,250.00.

How can I contact NephroGenex?

NephroGenex's mailing address is PO Box 400, JAMISON, PA 18929-0400, United States. The healthcare company can be reached via phone at +1-609-5538887.

MarketBeat Community Rating for NephroGenex (NRXGQ)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  71 (Vote Outperform)
Underperform Votes:  59 (Vote Underperform)
Total Votes:  130
MarketBeat's community ratings are surveys of what our community members think about NephroGenex and other stocks. Vote "Outperform" if you believe NRXGQ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NRXGQ will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.